Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 226,057,773 papers from all fields of science
Search
Sign In
Create Free Account
Am 80
Known as:
N-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)terephthalamic Acid
, Am-80
, 4-((5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl)
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
SY-1425
TM-411
Broader (1)
tamibarotene
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Am80, a retinoic acid receptor agonist, ameliorates murine vasculitis through the suppression of neutrophil migration and activation.
C. Miyabe
,
Y. Miyabe
,
+14 authors
T. Nanki
Arthritis & Rheumatism
2013
Corpus ID: 10976851
OBJECTIVE Vasculitis is characterized by leukocyte infiltration in the vessel walls, with destructive damage to mural structures…
Expand
2011
2011
All‐trans retinoic acid and a novel synthetic retinoid tamibarotene (Am80) differentially regulate CD38 expression in human leukemia HL‐60 cells: possible involvement of protein kinase C‐δ
A. Uruno
,
N. Noguchi
,
+8 authors
A. Sugawara
Journal of Leukocyte Biology
2011
Corpus ID: 5270898
ATRA and a synthetic RAR agonist tamibarotene (Am80) induce granulocytic differentiation of human acute leukemia HL‐60 cells and…
Expand
2009
2009
Oral administration of synthetic retinoid Am80 (Tamibarotene) decreases brain beta-amyloid peptides in APP23 mice.
K. Kawahara
,
K. Nishi
,
+8 authors
H. Nakayama
Biological and Pharmaceutical Bulletin
2009
Corpus ID: 31906416
The purpose of this study is to investigate whether a synthetic retinoid Am80 (tamibarotene) exhibits any improving effects on…
Expand
2009
2009
Retinoid ameliorates experimental autoimmune myositis, with modulation of Th cell differentiation and antibody production in vivo.
Naho Ohyanagi
,
Miwako Ishido
,
+4 authors
T. Nanki
Arthritis & Rheumatism
2009
Corpus ID: 30884
OBJECTIVE Polymyositis and dermatomyositis are chronic inflammatory muscle diseases. Retinoids are compounds that bind to the…
Expand
2009
2009
Oral administration of synthetic retinoid Am80 inhibits the development of type 1 diabetes in non-obese diabetic (NOD) mice.
I. Miwako
,
K. Shudo
Biological and Pharmaceutical Bulletin
2009
Corpus ID: 22355216
Synthetic retinoid Am80 is a potent modulator of the immune system. Am80 is effective in various experimentally induced…
Expand
Review
2002
Review
2002
New advances in the treatment of acute promyelocytic leukemia
D. Douer
International journal of hematology
2002
Corpus ID: 8295743
Objecive: Describe the treatment options of newly diagnosed and relapsed APL. Induction: The fusion PML/RAR gene provided the…
Expand
Highly Cited
1999
Highly Cited
1999
Effect of Am-80, a Synthetic Derivative of Retinoid, on Experimental Arthritis in Mice
H. Nagai
,
S. Matsuura
,
+4 authors
K. Shudo
Pharmacology
1999
Corpus ID: 46819874
Am-80 is a newly snythesized retinoid with the structure of one aromatic amide among retinobenzoic acids. It exhibits specific…
Expand
1997
1997
Anticoagulant effects of synthetic retinoids mediated via different receptors on human leukemia and umbilical vein endothelial cells.
M. Shibakura
,
T. Koyama
,
+4 authors
S. Hirosawa
Blood
1997
Corpus ID: 39459784
We recently found that retinoic acids (RAs) exert anticoagulant effects by upregulating thrombomodulin (TM) and downregulating…
Expand
Review
1996
Review
1996
Successful Treatment of Relapse of Acute Promyelocytic Leukemia with a New Synthetic Retinoid, Am80
A. Takeshita
,
Yukiko Shibata
,
+6 authors
R. Ohno
Annals of Internal Medicine
1996
Corpus ID: 6513264
All-trans retinoic acid (ATRA) has proven to be a major advance in the management of patients with acute promyelocytic leukemia…
Expand
1996
1996
Novel synthetic retinoic acid inhibits rat collagen arthritis and differentially affects serum immunoglobulin subclass levels
K. Kuwabara
,
K. Shudo
,
Y. Hori
FEBS Letters
1996
Corpus ID: 32046159
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE